Prioritizing future research on off-label prescribing: Results of a quantitative evaluation

Pharmacotherapy

Volumn 28, Issue 12, 2008, Pages 1443-1452

  Walton, Surrey M ^a,b   Schumock, Glen T ^a,b   Lee, Ky Van ^a,c   Alexander, G Caleb ^a,d,e   Meltzer, David ^a,d,f   Stafford, Randall S ^a,c  

^a Chicago Area Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Center   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Off label drug use; Research prioritization; Value of information

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CELECOXIB; CLONAZEPAM; DEXAMETHASONE; DIGOXIN; DULOXETINE; ESCITALOPRAM; ESOMEPRAZOLE; GABAPENTIN; LISINOPRIL; LORAZEPAM; METRONIDAZOLE; MONTELUKAST; OLANZAPINE; PARACETAMOL PLUS TRAMADOL; PREDNISOLONE; PROMETHAZINE; QUETIAPINE; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; SALBUTAMOL; SERTRALINE; TRAZODONE; VANCOMYCIN; VENLAFAXINE; WARFARIN; ZOLPIDEM;

ARTICLE; ASTHMA; CHRONIC KIDNEY FAILURE; DEPRESSION; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HYPERTENSION; INTERNET; JOINT INJURY; KIDNEY FAILURE; OFF LABEL DRUG USE; PRESCRIPTION; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 57149085867     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.12.1443     Document Type: Article

References (25)

1. Chen H, Deshpande AD, Jiang R, Martin BC. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 2005;14:629-38.
2. Ma J, Lee K-V, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005;37:434-42.
3. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States, 1995-2000. Am J Med 2005;118:259-68.
4. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000;83:498-501.
5. Loder EW, Biondi DM. Off-label prescribing of drugs in specialty headache practice. Headache 2004;44:636-41.
6. Donofrio PD, Busis NA. Regulatory and reimbursement issues in treating patients with immune-mediated neuropathies. Neurology 2002;59:S41-5.
7. Strom BL, Melmon KL, Miettinen OS. Post-marketing studies of drug efficacy: why? Am J Med 1985;78:475-80.
8. Adams C, Young A. Risky Rx: A Knight Ridder investigation. Newspaper article series, November 2-4, 2003. Available from http://www.realcities.com/mld/krwashington/news/special_packages/riskyrx/. Accessed September 18, 2008.
9. Radley D, Finkelstein S, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006:166:1021-6.
10. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 1999;8:269-74.
11. IMS Health. National disease and therapeutic index, medication reference file, 2001. Plymouth Meeting, PA: IMS Health, 2007.
12. Thomson Micromedex. Drugdex system [internet database]. Greenwood Village, CO: Thomson Micromedex.
13. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the national disease and therapeutic index and the national ambulatory medical care survey to evaluate antibiotic usage. Proceedings of the section on survey research methods, American Statistical Association. Alexandria, VA: American Statistical Association, 2000:840-5.
14. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
15. U.S. Public Health Service. International classification of diseases, ninth revision, clinical modification. Washington DC: U.S. Department of Health and Human Services, 1988.
16. Thomson Micromedex. PDR electronic library [internet database]. Greenwood Village, CO: Thomson Micromedex.
17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. FDA approved drugs. Available from www.accessdata.fda.gov/scripts/ cder/drugsatfda. Accessed April 26, 2007.
18. IMS Health. IMS national prescription audit data accessed through Dataview 4.0. Plymouth Meeting, PA: IMS Health, 2007.
19. U.S. Food and Drug Administration. FDA orange book. Available from http://www.fda.gov/cder/ob/. Accessed April 24, 2007.
20. U.S. Food and Drug Administration. NDAs/ANDAs approved since 1939 (electronic report obtained under a Freedom of Information Act request). Rockville MD: Food and Drug Administration, 2004.
21. IMS Health. IMS Health office promotion report data accessed through Dataview 4.0. Plymouth Meeting, PA: IMS Health, 2007.
22. TNS Media Intelligence. Ad$pender survey. New York, NY: TNS Media Intelligence, 2007.
23. Shekelle P, Maglione M, Bagley S, et al. Comparative effectiveness review no. 6 (prepared by the Southern California/RAND evidence-based practice center under contract no. 290-02-0003). Rockville, MD: Agency for Healthcare Research and Quality, January 2007.
24. Sachs GS, Nierenberg AA, Calabrese JR, et. al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22.
25. Kennedy A, Littenberg B. A modified outpatient prescription form to reduce prescription errors. Jt Comm J Qual Saf 2004;30:480-7.